Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M9,157Revenue $M362Net Margin (%)0Z-Score0
Enterprise Value $M9,157EPS $-2.9Operating Margin %0F-Score0
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %0Quick Ratio0Cash flow > EarningsN
Price/Sales05-y EBITDA Growth Rate %0Current Ratio0Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)0Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M0ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with ONXX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
ONXXMario Gabelli 2013-09-30 Buy 0.47%$110.99 - $136.03
$ 124.70-2%New holding644,979
ONXXPrem Watsa 2013-09-30 Buy 0.04%$110.99 - $136.03
$ 124.70-2%New holding4,500
ONXXMariko Gordon 2013-09-30 Sold Out -0.03%$110.99 - $136.03
$ 124.70-2%Sold Out0
ONXXMariko Gordon 2013-06-30 Add0.01%$81.76 - $100.37
$ 124.7026%Add 72.04%7,138
ONXXAndreas Halvorsen 2012-09-30 Sold Out -0.69%$64.73 - $85.82
$ 124.7041%Sold Out0
ONXXVanguard Health Care Fund 2012-09-30 Reduce-0.1%$64.73 - $85.82
$ 124.7041%Reduce -24.40%1,022,700
ONXXAndreas Halvorsen 2012-06-30 Buy 0.69%$37.11 - $66.36
$ 124.7063%New holding1,275,921
ONXXGeorge Soros 2011-03-31 Add0.06%$34.05 - $37.67
$ 124.7071%Add 1576.09%154,200
ONXXGeorge Soros 2010-09-30 Buy 0.01%$19.9 - $28.11
$ 124.7080%New holding17,900
ONXXVanguard Health Care Fund 2010-06-30 Add0.06%$21.7 - $31.18
$ 124.7079%Add 61.03%1,299,865
ONXXVanguard Health Care Fund 2009-09-30 Add0.03%$27.23 - $36.55
$ 124.7075%Add 32.94%807,200
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ONXX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!

ONXX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Torley HelenEVP, Chief Commercial Officer 2013-08-12Sell9,311$126.89-1.73view
Fust Matthew KEVP & CFO 2013-08-08Sell2,492$128.21-2.74view
SHEMA SUZANNE MEVP, GC and Corp. Secretary 2013-08-07Sell4,052$131.86-5.43view
Foster-Cheek Kaye ISVP, Global Human Resources 2013-08-06Sell8,878$132.81-6.11view
Nevinny Corinne HDirector 2013-07-30Sell1,500$131.26-5view
GRILLO LOPEZ ANTONIO JDirector 2013-07-30Sell1,500$131.26-5view
Fust Matthew KEVP & CFO 2013-07-26Sell6,043$130.5-4.44view
GRILLO LOPEZ ANTONIO JDirector 2013-07-26Sell2,000$130.5-4.44view
SHEMA SUZANNE MEVP, GC and Corp. Secretary 2013-07-08Sell4,052$135.76-8.15view
Fust Matthew KEVP & CFO 2013-07-02Sell1,551$132.8-6.1view

Press Releases about ONXX :

    Quarterly/Annual Reports about ONXX:

      News about ONXX:

      Articles On GuruFocus.com
      Amgen: Stronger Drug Portfolio with Acquisition Oct 28 2014 
      Amgen: Stronger Drug Portfolio with Acquisition Sep 22 2014 
      Mario Gabelli Comments on Onyx Pharmaceuticals Inc. Jan 03 2014 
      Columbia Wanger’s Third Quarter Selling Nov 20 2013 
      6 New Stock Picks from Prem Watsa Nov 19 2013 
      Edward Owens’ Vanguard Health Care Fund Does More Shedding than Adding in Third Quarter Nov 01 2012 
      ONYX Pharmaceuticals Inc. (ONXX) EVP & COO Laura Brege sells 12,500 Shares Jan 20 2011 
      ONYX Pharmaceuticals Inc. (ONXX) CFO Matthew K Fust sells 1,812 Shares Jan 08 2011 
      ONYX Pharmaceuticals Inc. (ONXX) President & CEO N Anthony Coles sells 13,669 Shares Dec 09 2010 
      ONYX Pharmaceuticals Inc. (ONXX) EVP & COO Laura Brege sells 25,000 Shares Nov 10 2010 

      More From Other Websites
      Here are some Bay State firms working on drugs to treat Alzheimer's Mar 17 2015
      Could Amgen layoffs in California bring more biotech workers to Washington state? Mar 11 2015
      Why the Onyx experiment failed and why it matters Mar 11 2015
      Amgen to lay off 300 at Onyx, close South S.F. facility Mar 10 2015
      Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority of Kyprolis® (carfilzomib) Over... Mar 01 2015
      Amgen Announces the European Medicines Agency Acceptance of Kyprolis® (carfilzomib) Marketing... Feb 26 2015
      Amgen Announces New Data from Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study in Patients... Dec 07 2014
      Amgen and Onyx Announce Detailed Results from Phase 3 ASPIRE Study of Kyprolis® (carfilzomib) in... Dec 06 2014
      Amgen Highlights New Data in The Treatment of Blood Cancers at ASH 2014 Nov 06 2014
      AstraZeneca buys US cancer drugs firm Aug 27 2013
      US biotech giant Amgen to buy rival Onyx for $10.4 bln Aug 25 2013

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial